BREAKING
Altisource Portfolio Solutions Releases Q1 2026 Financial Results 2 minutes ago Valley National Bancorp Releases Q1 2026 Financial Results 9 minutes ago Nasdaq Releases Q1 2026 Financial Results 11 minutes ago City Holding Releases Q1 2026 Financial Results 12 minutes ago MarineMax Releases Q2 2026 Financial Results 18 minutes ago LSI Industries Releases Q3 2026 Financial Results 18 minutes ago Dover Releases Q1 2026 Financial Results 20 minutes ago American Airlines Group Releases Q1 2026 Financial Results 29 minutes ago Keurig Dr Pepper Q1 2026 Financial Review 30 minutes ago PENN Entertainment Releases Q1 2026 Financial Results 37 minutes ago Altisource Portfolio Solutions Releases Q1 2026 Financial Results 2 minutes ago Valley National Bancorp Releases Q1 2026 Financial Results 9 minutes ago Nasdaq Releases Q1 2026 Financial Results 11 minutes ago City Holding Releases Q1 2026 Financial Results 12 minutes ago MarineMax Releases Q2 2026 Financial Results 18 minutes ago LSI Industries Releases Q3 2026 Financial Results 18 minutes ago Dover Releases Q1 2026 Financial Results 20 minutes ago American Airlines Group Releases Q1 2026 Financial Results 29 minutes ago Keurig Dr Pepper Q1 2026 Financial Review 30 minutes ago PENN Entertainment Releases Q1 2026 Financial Results 37 minutes ago
ADVERTISEMENT
Breaking News

Thermo Fisher Scientific Releases Q1 2026 Financial Results

Thermo Fisher Scientific Inc. (TMO) reported Q1 2026 adjusted earnings of $5.44 per share, beating the $5.28 consensus estimate (beat by 3.0%).

April 23, 2026 1 min read

Thermo Fisher Scientific Inc. (TMO) reported Q1 2026 adjusted earnings of $5.44 per share, beating the $5.28 consensus estimate (beat by 3.0%).

TMOTMO|EPS $5.44 vs $5.28 est (+3.0%)|Rev $11.01B|Net Income $1.65B

Thermo Fisher Scientific Inc. (TMO) reported Q1 2026 adjusted earnings of $5.44 per share, beating the $5.28 consensus estimate (beat by 3.0%). Revenue totaled $11.01B for the quarter. Revenue was up 6.0% year-over-year.

Thermo Fisher Scientific Inc. is a Diagnostics & Research company. Organic revenue growth was +1.0% for the quarter. Laboratory Products and Biopharma Services generated $6.04B in revenue for the quarter. The company earned $2.03B in adjusted net income.

Wall Street consensus stands at 20 buy, 4 hold, 0 sell.

A detailed analysis of Thermo Fisher Scientific Inc.’s quarter follows shortly on AlphaStreet.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT